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  Introduction 
 Follicular non-Hodgkin lymphoma (f-NHL) is a slow-growing 
(indolent) subtype of NHL that constitutes approximately 
20 – 25% of all NHL and 70% of indolent lymphomas [1]. While 
f-NHL is considered incurable with currently available thera-
pies, the 5-year survival rate is around 70% [2] with median 
survival being 8  –  10 years [3,4]. Often patients are not treated 
when fi  rst diagnosed if no symptoms are present. Th  e  natural 
history of f-NHL is characterized by continuous risk of relapse 
and progression, with each event becoming less sensitive to 
treatment and each remission shorter than the preceding one 
[5,6]. Th  is makes disease management challenging, with a 
wide array of treatment options ranging from watchful wait-
ing to intensive therapies that are typically aimed at delaying 
disease relapse and progression with fewest adverse eff  ects. 
 Th  e safety and eff   ectiveness of rituximab (an anti-
CD20 antibody) resulted in the widespread use of this 
agent in the treatment of f-NHL as either monotherapy 
or in combination with chemotherapy [7,8]. Rituximab 
added to chemotherapy has demonstrated signifi  cant 
increases in response rates, response duration, and over-
all survival as either fi  rst-line or relapse treatment in NHL 
[9  –  12]. Consolidation therapy with rituximab followed by 
  90  Y-ibritumomab tiuxetan in patients with f-NHL who 
achieved complete or partial response after fi  rst-line induc-
tion therapy prolonged progression-free survival (PFS) [13]. 
Th   e use of maintenance rituximab after chemotherapy has 
been shown to be superior to observation among patients 
with NHL not previously treated with rituximab [14,15]. 
Further, maintenance rituximab was benefi  cial in patients 
with f-NHL who achieved a partial or complete remis-
sion after initial single-agent fi  rst-line rituximab therapy 
[16,17]. Maintenance rituximab signifi  cantly  improved 
PFS compared with observation after induction with both 
chemotherapy alone and rituximab plus chemotherapy 
in relapsed/resistant f-NHL [18,19]. Most recently, data 
presented from a large international phase III trial dem-
onstrated that patients with advanced f-NHL treated with 
rituximab maintenance had a 50% reduction in risk of 
progressive disease (PD) relative to patients who did not 
receive rituximab maintenance [20,21]. 
  While current treatments have demonstrated improved 
clinical outcomes among patients with f-NHL, growing con-
straints on healthcare resources are making it increasingly 
important to also evaluate economic outcomes associated 
with therapy. Several studies have compared the cost-eff  ec-
tiveness of treatment alternatives, and found that the use of 
rituxumab is cost-eff  ective in the fi  rst-line [22] and relapsed 
maintenance settings [23]. Kutikova   et al  ., in a study evaluat-
ing medical costs associated with NHL in the fi  rst 2 years of 
treatment, found that treatment failure was the most expen-
sive clinical scenario [24]. Past economics studies, however, 
are limited in geographic range and are often restricted to the 
clinical trial setting. Furthermore, no studies have directly 
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evaluated the economic consequences of PD following a 
positive treatment response. 
 Th   e goal of this study was to quantify the incremental cost 
of PD and associated healthcare resource utilization (HRU) 
among patients with f-NHL following successful fi  rst-line 
therapy within a large geographically dispersed network 
of community-based outpatient oncology practices in the 
United States. Results of this study may help to quantify 
the economic benefi  ts of delaying progression of f-NHL in 
the real-world setting.     
  Materials and methods   
 Data sources 
 Th   is study utilized clinical data from US Oncology ’ s iKnowMed 
oncology-specifi  c electronic medical record (EMR) system. 
Th  is system captures demographic, clinical, and treatment 
data for patients receiving care within US Oncology  ’  s net-
work of approximately 1200 community-based oncologists. 
During the study time period, the iKnowMed EMR system 
was implemented across approximately 82% of the US 
Oncology network. It is estimated that iKnowMed captures 
data on approximately 5  –  6% of all newly diagnosed patients 
with NHL in the United States, in a setting where patients are 
treated according to usual clinical practice with no criteria 
for therapy selection and no schedule of visits imposed. 
  To estimate outpatient cost of care, we linked patients 
with NHL identifi  ed in the iKnowMed EMR to US Oncology ’ s 
Claims Data Warehouse (CDW). Th   e CDW repository houses 
all claims for services provided within the US Oncology 
network. Data include HCPCS/CPT (Healthcare Common 
Procedure Coding System/Current Procedural Terminology) 
codes and descriptions, date of service, quantity, amount 
billed, and primary payer. Data were de-identifi  ed  and 
accessed in compliance with the Health Insurance Portabil-
ity and Accountability Act. Th   erefore, approval by an institu-
tional review board was not required.     
 Study population 
  Using a retrospective cohort design, we identifi  ed a pool of 
2005 patients with f-NHL in iKnowMed who achieved par-
tial or complete remission or had documented stable dis-
ease or progression from 1 July 2006 to 30 December 2009. 
Treatment response and PD were classifi  ed according to 
standard response criteria [25]. Patients were categorized 
into two cohorts depending on their experience of PD dur-
ing the study catchment period. Incidence of PD was identi-
fi  ed by a documented disease status of  ‘ progressive disease ’  
following a period of remission or stable disease. Patients 
who did not progress were identifi  ed by a documented dis-
ease  status  of   ‘ partial  remission, ’    ‘ complete  remission, ’   or 
 ‘ stable  disease. ’  
 Th  ere were 282 (14%) patients with PD and 1723 (86%) 
without. Of these, we linked 1865 (93%) to the CDW. We 
excluded 36 patients (fi  ve with PD and 31 without PD) who 
were enrolled in another clinical trial or received treatment 
for another cancer, and 848 patients (nine with PD and 839 
without PD) who were identifi  ed as having second opinion/
consult only. Th  e identifi  cation of second opinion/consult 
only cases was based on having fewer than 30 days of total 
follow-up in iKnowMed with incomplete demographic and 
clinical characteristics. After applying the inclusion and 
exclusion criteria, a total of 1002 patients with f-NHL were 
included in the fi  nal study population: 734 in the   ‘  no PD  ’   
cohort and 268 patients in the   ‘  PD  ’   cohort. 
  Follow-up time was censored at the last entry for disease 
status, end of 12 months, or study end (31 December 2010). To 
calculate the cost of progression, we adopted a phase of care 
approach using a 6-month window from the date of disease 
progression, as the majority of re-treatment costs are usually 
seen within this time period [26  –  28]. Th   e study index date 
(baseline) was the date of PD or the initial date in the study 
catchment period for those with no PD. Data were collected 
at baseline on patient demographics (age at diagnosis and 
gender), clinical characteristics (stage at diagnosis, presence 
of B-symptoms, hemoglobin [HGB] levels, lactate dehydro-
genase [LDH] levels, performance status, and nodal status) 
as well as payer type. Th   e number of lymph nodes and extent 
of spread to the lymph nodes is captured in the iKnowMed 
data based on the TNM staging, which captures the extent of 
the tumor (T), extent of spread to the lymph nodes (N), and 
presence of distant metastasis (M). For laboratory values, 
performance status, and nodal status, we captured the clos-
est entry within 14 days of the index date.     
 Statistical analysis 
  Patients were described at baseline with respect to demo-
graphic and clinical characteristics overall and stratifi  ed 
by progression status.   χ  2   tests for categorical variables and 
  t  -tests for continuous variables determined statistically sig-
nifi  cant diff  erences by progression status. 
 Costs were estimated based on unadjusted 2007 Medicare 
reimbursement rates, Geographic Practice Cost Index (GPCI) 
93. While reimbursement rates were available for the large 
majority (97%) of charges, for the remaining charges missing 
a Medicare rate we imputed costs using a median charge-to-
cost ratio that was calculated using all codes for which Medi-
care reimbursement was available. Costs were calculated 
using a standard cost per patient per month (PPPM) metric. 
For months in which a patient did not accrue costs, a value 
of zero was applied to ensure that those patient-months were 
included in the denominator for the costs PPPM calculations. 
Costs were reported overall and by health resource category. 
Unadjusted costs were compared between PD cohorts using 
the  Mann – Whitney   U -test. 
  We developed econometric models to adjust for clini-
cal and demographic diff  erences that may confound the 
observed association between progression status and cost 
of care. A backward elimination approach was utilized to 
identify signifi  cant predictors of total costs. Age at diagnosis, 
gender, stage at diagnosis, presence of B-symptoms, base-
line HGB, baseline LDH, number of positive lymph nodes, 
and baseline performance status were considered as pos-
sible covariates. PD was included as an indicator variable. 
Standard model diagnostics was carried out including tests 
for multicollinearity and heteroscedasticity, and appropri-
ate estimation methods were employed (e.g. calculating 
heteroscedasticity-robust standard error [SE]) [29]. Cost of follicular lymphoma progression  2119
  To provide a more comprehensive evaluation of the 
extent of HRU for patients who did and did not progress, 
we compared the frequency at which patients received care 
over a 6-month period. Using claims data, we compared the 
number of billed outpatient physician visits, acute care visits 
(inpatient and emergency room [ER] admissions), outpa-
tient chemotherapy infusion visits, and outpatient labora-
tory procedures by progression status. Th  ese frequencies 
were measured on a PPPM basis and   t -tests/Mann – Whitney 
  U  -tests (depending on the normality of data) were used to 
determine statistical signifi  cance. Statistical analyses were 
conducted with SPSS version 15 and SAS version 9.1. All 
statistical tests were interpreted at   α     0.05,  two-tailed.    
 Results 
  Table I shows the baseline clinical and demographic char-
acteristics of patients overall and by progression status. 
Th   e overall median age at diagnosis was 61 years and 36% 
of patients were older than 65. Th  ere were no signifi  cant 
diff  erences in age at diagnosis and gender between PD and 
non-PD patients. Overall 44% of patients were male and 
56% were female. While there was no signifi  cant diff  erence 
in the percentage of patients presenting with B-symptoms 
at diagnosis, patients who progressed were more likely to 
present with advanced stage at diagnosis compared to non-
PD patients (41% vs. 32%;   p       0.06). Lymph node status, 
baseline (measured at index date) laboratory values (HGB 
and LDH), and performance status were signifi  cantly worse 
for patients with PD compared to non-PD. Th   e vast majority 
of patients were covered by Medicare (53%) or had private 
insurance (44%). 
 Th   e majority of patients with PD (  n      186; 69%) received 
post-progression infusion therapy (Table II). Of these 
patients, 69 (37%) received rituximab monotherapy, 110 
(59%) received rituximab in combination with chemotherapy, 
    Table I. Patient characteristics at baseline.   
Characteristic Total (  n      1002) No progression (  n     734) Progression  ( n     268)  p -Value
Age at diagnosis,   n   (%)
        55 333 (33) 258 (35) 75 (28) 0.10
    55 – 65 313  (31) 222  (30) 91  (34)
        65 356 (36) 254 (35) 102 (38)
    Mean  age 60.1 59.6 61.3
    Median  age  (range) 61  (21 – 91) 60  (21 – 91) 61  (27 – 90) 0.10
Gender,   n   (%)
      Female 565 (56) 430 (59) 135 (50) 0.02
      Male 437 (44) 304 (41) 133 (50)
Stage,   n   (%)
      I 187 (20) 147 (21) 40 (16) 0.06
      II 198 (21) 150 (22) 48 (19)
      III 234 (25) 170 (25) 64 (25)
      IV 327 (35) 223 (32) 104 (41)
    Missing 56 44 12
B-symptoms,   n   (%)
      No 812 (85) 601 (87) 211 (82) 0.11
      Yes 138 (15) 93 (13) 45 (18)
    Missing 52 40 12
HGB    12 * ,   n   (%)
      No 668 (81) 502 (85) 166 (73)     0.0001
      Yes 152 (19) 90 (15) 62 (27)
    Missing 182 142 40
Elevated  LDH * ,   n   (%)
      No 477 (86) 353 (89) 124 (80) 0.01
      Yes 76 (14) 45 (11) 31 (20)
    Missing 449 336 113
4     positive nodes,   n   (%)
      No 543 (67) 412 (70) 131 (58) 0.0008
      Yes 272 (33) 176 (30) 96 (42)
    Missing 187 146 41
ECOG  PS * ,   n   (%)
      0 581 (68) 445 (71) 136 (60) 0.0005
      1 209 (25) 145 (23) 64 (28)
    2    60 (7) 33 (5) 27 (12)
    Missing 152 111 41
Payer type
      Private 438 (44) 330 (45) 108 (40) 0.06  * 
      Medicare 537 (53) 381 (52) 156 (58)
      Medicaid 9 (1) 6 (1) 3 (1)
      Other 18 (2) 17 (2) 1 (0)
Follow-up time,   n   (%)
        12  months 56 (6) 28 (4) 30 (11)
        12  months 938 (94) 700 (96) 236 (89)
      Mean follow-up time, months 35.1 37.0 29.8
    Median  follow-up,  months  (range) 37  (1 – 53) 39  (3 – 53) 32  (1 – 53)
Alive at end of follow-up,   n   (%) 983 (99) 725 (99.6) 258 (97)
  HGB, hemoglobin; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group Performance Status. 
        *  Based on entry in iKnowMed closest to index date (    14  days).     2120  R. Beveridge et al.
patients with PD was   $  21 621 vs.   $  5226 for non-PD patients. 
At 12-months, the cumulative total cost for patients with PD 
was   $  30 890 vs.   $  8704 for non-PD patients. Table III presents 
a comparison of mean costs PPPM by progression status. 
Average costs PPPM over the 6-month follow-up period for 
patients with PD were   $  2667 more than for non-PD patients 
(  p     0.001), with a relative cost four times higher. Diff  erences 
in cost were signifi  cant in all categories. 
 In  a  level – level  multivariable regression model (Table IV) 
adjusting for baseline hemoglobin level, number of positive 
lymph nodes at diagnosis, baseline performance status, and 
progression status remained signifi  cantly associated with 
total outpatient costs. PD was associated with an increased 
cost of  $ 2557 per month, all else being equal. Due to the pres-
ence of heteroscedasticity as diagnosed using the Breusch  –
 Pagan test, this model includes robust-SEs. In another model 
including log-transformed cost as the dependent variable 
and seven (4%) received chemotherapy only. Among the 
non-PD group, 195 (27%) received infusion therapy. Th  e 
majority of these patients (  n      147; 75%) received rituximab 
monotherapy, while 44 (23%) received rituximab in combi-
nation with chemotherapy and four (2%) received chemo-
therapy alone. To further verify why some non-PD patients 
received chemotherapy other than maintenance rituximab, 
we conducted an electronic chart review of a random sample 
of this group and found that chemotherapy administered was 
typically given to complete a planned chemotherapy regi-
men following treatment response (i.e. consolidation). For 
example, the typical non-PD patient who had chemotherapy 
and rituximab charges actually only received chemotherapy 
for a short time following treatment response and then sub-
sequently received rituximab maintenance therapy. 
  Figure 1 shows the cumulative total cost over 12 months 
by progression status. Th   e cumulative 6-month total cost for 
    Figure 1.         Cumulative 12-month total cost by progression status.   
    Table II. Description of infusion therapy by progression status after index date.   
Infused therapy Total (  n      1002) No progression (  n     734) Progression  ( n     268)
Infusion therapy
      No 621 (61.9%) 539 (73.4%) 82 (30.5%)
      Yes 381 (38.1%) 195 (26.5%) 186 (69.4%)
        Rituximab  monotherapy 216  (21.6%) 147  (75.4%) 69  (37.1%)
        Rituximab-chemotherapy 154  (15.4%) 44  (22.5%) 110  (59.1%)
        Chemotherapy  only 11  (1.1%) 4  (2.1%) 7  (3.8%)
Chemotherapy agents
    Rituximab-chemotherapy 154 44 110
        Cyclophosphamide 108 33 75
        Vincristine 101 32 69
        Doxorubicin 41 16 25
        Fludarabine 23 3 20
        Other 203 46 157
    Chemotherapy  only 11 4 7
        Cyclophosphamide 6 2 4
        Vincristine 4 1 3
        Doxorubicin 2 1 1
        Etoposide 1 1 0
        Other 10 2 8     Anemia with (  6   R)CHOP in non-Hodgkin lymphoma      2121
(Table IV), PD was found to be independently associated 
with a two-fold higher cost after adjusting for potential 
confounders. 
  Table V presents health resource utilization by progres-
sion status. Patients who experienced PD had a 23% higher 
frequency of outpatient physician visits than non-PD patients 
(  p       0.001). A two-fold higher frequency was observed for 
outpatient laboratory visits (  p       0.001) in PD vs. non-PD 
patients. Patients with PD were signifi  cantly more likely to 
receive chemotherapy than non-PD patients (72% vs. 29%, 
respectively;  p     0.001). Further, among patients who received 
chemotherapy, those who progressed had a signifi  cantly 
higher frequency of chemotherapy infusion visits (  p     0.001), 
suggesting that patients who progress receive more intensive 
chemotherapy regimens than those who do not progress (the 
majority of whom receive maintenance rituximab). Similarly, 
patients with PD were signifi  cantly more likely to have an 
inpatient admission or ER visit than non-PD patients (18% vs. 
4%;  p     0.001), although the mean number of acute care visits 
PPPM did not diff  er by progression status.     
 Discussion 
  For a relatively indolent cancer such as f-NHL, for which 
treatment options range from watchful waiting to costly 
stem-cell transplant, rational treatment selection should 
include consideration of both the medical effi   cacy and the 
economic outcomes of the available treatment options. 
Results of this retrospective study highlight and quantify 
the economic costs of progression among patients with 
f-NHL treated within an outpatient community-based set-
ting. Using linked EMR and claims data from a large cohort 
of patients, we provide further evidence to support the 
hypothesis that treatment strategies that delay or prevent 
progression not only improve clinical outcomes but also 
provide substantial economic benefi  ts in lowering the costs 
of care in NHL. 
  Findings from this study add to the literature in that it is 
the fi  rst study to estimate the cost of progressed f-NHL and 
the burden of progression on the healthcare system. Th  e  few 
studies that have assessed the economic burden of NHL are 
subject to the following limitations: restricted to specifi  c geo-
graphic regions, clinical trial setting, or a single employer; 
did not diff  erentiate between NHL subtypes; and did not 
diff  erentiate between treatment phase or progression status 
[30 – 32]. A recent study by Kutikova and colleagues evaluated 
medical costs by NHL subtype (indolent and aggressive), 
but examined costs of progression only for patients with 
aggressive NHL [24]. Th   e current analysis accounts for these 
limitations and provides data for the cost of progression in a 
diverse group of patients with indolent NHL. 
 Th   e present study showed that patients with f-NHL who 
progressed were more likely to have been diagnosed with 
advanced disease, have four or more positive lymph nodes, 
    Table IV. Multivariable regression analysis of mean cost per patient per month.   
Covariate
Untransformed model Log-transformed model
Coeffi   cient 95% CI   p -Value Coeffi   cient 95% CI   p -Value
Progression status
    No Referent Referent
    Yes 2557.20 2090.90 – 3023.49    0.001 2.29 1.94 – 2.64    0.001
Hemoglobin   12
    No Referent Referent
    Yes 783.65 283.73 – 1283.57 0.002 1.01 0.64 – 1.38    0.001
4    positive  nodes
    No Referent Referent
    Yes 558.92 166.99 – 950.84 0.005 0.62 0.28 – 0.95    0.001
ECOG PS
    0 Referent Referent
    1 611.48 180.07 – 1042.89 0.006 0.65 0.28 – 1.02 0.001
    2 168.26 602.06 – 938.60 0.66 0.21 0.36 – 0.80 0.46
   CI,  confi  dence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status.     
    Table III. Six-month mean cost per patient per month overall and by category.   
Service No progression (  n     734) Progression  ( n     268) C P     C NP C  P /C NP   p -Value * 
Overall cost 859.98 3527.4 2667.4 4.10    0.001
    Outpatient  visits 36.68 99.92 63.24 2.72    0.001
    Acute  care  †  2.46 24.14 21.68 9.81    0.001
    Chemotherapy 655.75 2495.01 1839.26 3.8    0.001
        R-mono 487.07 849.50 362.43 1.74    0.001
        R-chemo 166.07 1610.86 1444.79 9.69    0.001
        Chemo 2.61 34.65 32.04 13.27    0.001
    Other  medication 101.86 700.28 598.42 6.87    0.001
    Laboratories 11.35 28.53 17.18 2.51    0.001
    Minor  procedures 2.79 8.79 6.00 3.15    0.001
    Other 0.59 3.02 2.43 5.11    0.001
    XRT 15.07 71.27 38.93 4.72    0.001
    RAD  non-XRT 32.59 95.41 62.82 2.92    0.001
 C P  , cost of progression; C  NP  , cost of not progressing; R-mono, rituximab monotherapy; R-chemo, rituximab-chemotherapy; Chemo, chemotherapy only; XRT, external 
radiation treatment; RAD non-XRT, radiation other than XRT. 
    * Mann – Whitney   U -test.   
   †  Inpatient  and  ER  visits.     2122  R. Beveridge et al.
available, which limited the number of covariates that 
could be included in the multivariate analysis. We followed 
patients for a maximum of 6 months, which may have led to 
an underestimation of reported costs and the rate of treat-
ment failure or PD. While the claims data used to estimate 
costs for this analysis included primarily outpatient medical 
oncology services, we also captured charges for radiologic 
services and inpatient consultation visits. However, costs for 
these services may be underestimated due to the possibil-
ity that patients may have received these outside of the US 
Oncology network. 
  However, despite these limitations, this study provides 
new information regarding the economic impact of PD in 
patients with f-NHL. As survival improves, the number of 
patients living with the disease is expected to rise. Patients 
whose disease has progressed may still have a relatively 
long survival with conventional management [33]. As a 
result, physicians will continue to navigate an increasing 
array of treatment options for this clinically heterogeneous 
group of patients. A better understanding of the economic 
outcomes associated with the disease and its treatment is 
essential in minimizing the burden to patients, caregivers, 
and society. Furthermore, while there is increasing scrutiny 
of the direct costs of prolonged treatment with targeted 
therapy, it is important to weigh these costs relative to the 
potential economic benefi  t of delaying progression. In this 
study, we objectively quantifi  ed the cost of PD, which plau-
sibly could be off  set by therapies that, while costly, have 
been demonstrated to yield signifi  cant clinical benefi  t in 
terms of delayed progression.          
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poor performance status, and high LDH and low HGB levels, 
consistent with other studies [33  –  35]. 
 Th  e overall crude cumulative total cost of progression 
over a 12-month follow-up period was   $  30 890, compared 
to   $  8704 for non-PD patients. Th   e mean cost PPPM among 
those who progressed was   $  2667 more than for patients who 
did not progress (  p      0.001), with a relative cost nearly four 
times higher. In multivariate analysis, PD remained signifi  -
cantly associated with a two-fold higher cost, adjusting for 
diff  erences in clinical factors. Th   ere are few studies of NHL 
costs with which to compare the results of this present study. 
Further, diff  erent patient populations, costing methodolo-
gies, and specifi  c objectives make direct comparisons across 
studies diffi   cult. In the only published US study of direct per-
patient costs for f-NHL, Gleeson  et al . estimated that the total 
direct costs for f-NHL in the fi  rst year following diagnosis was 
  $  36 000 [36]. In another study, the mean cost of treatment 
failure in aggressive NHL was   $  14 174 PPPM [24], which is 
signifi  cantly higher than the cost of progression estimated 
among patients with f-NHL in this study. However, diff  er-
ent subsets of the patient population with NHL (aggressive 
vs. indolent) were considered, and while our study focused 
solely on outpatient costs, the study by Kutikova  et al . consid-
ered inpatient costs as well [24]. 
  We found that patients who progressed had signifi  cantly 
higher frequencies of outpatient physician visits, laboratory 
procedures, acute care visits, and intensive chemotherapy 
regimens compared to non-PD patients. Th  is fi  nding  is 
supported by results from Kutikova   et al  . who showed that 
patients with both aggressive and indolent NHL had signifi  -
cantly higher resource use than controls [24]. 
  In interpreting the fi  ndings, several factors need to be 
considered. First, although data were collected from geo-
graphically dispersed community oncology practices, it is 
subject to selection bias due to convenience sampling where 
the study population may diff  er in unknown ways from the 
underlying patient population. Second, potential confound-
ing variables such as race, ethnicity, and income were not 
    Table V. Comparison of healthcare resource utilization by progression status.   
Service No progression (  n     798) Progression  ( n     204)  p -Value
Chemotherapy visits
    No 530  (72.2%) 77  (28.7%)    0.001
    Yes 204  (28.8%) 191  (72.3%)
    Visits  per  patient-month * 
        Mean 0.17 0.88    0.001
        Median  (range) 0.16  (0 – 2.84) 0.66  (0 – 5)    0.001
Outpatient physician visits
    Visits  per  patient-month
        Mean 0.47 1.23    0.001
        Median  (range) 0.33  (0.16 – 7) 1  (0.16 – 9.33)    0.001
Outpatient laboratory procedures
    Procedures  per  patient-month
        Mean 0.99 2.46    0.001
        Median  (range) 0.66  (0 – 15.6) 1.5  (0 – 16)    0.001
Acute care visits
    No 703  (95.7%) 220  (82%)    0.001
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